پريمولوت-نور Israel - arabă - Ministry of Health

پريمولوت-نور

bayer israel ltd - norethisterone acetate 5 mg - tablets - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

أبيترن ٥٠ Israel - arabă - Ministry of Health

أبيترن ٥٠

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

ريزدرونات تيڤع ٣٥ ملغ Israel - arabă - Ministry of Health

ريزدرونات تيڤع ٣٥ ملغ

abic marketing ltd - risedronic acid as sodium 35 mg - tablets - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

أكتونيل مرة في الشهر ١٥٠ ملغ Israel - arabă - Ministry of Health

أكتونيل مرة في الشهر ١٥٠ ملغ

sanofi - aventis israel ltd - risedronic acid as sodium 150 mg - film coated tablets - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

لوكوڤورين أقراص Israel - arabă - Ministry of Health

لوكوڤورين أقراص

abic ltd. - calcium folinate 15 mg - tablets - detoxifying agents for antineoplastic treatment - counteracts the action of folic acid antagonists. improves blood picture in megaloblastic anemias due to folate deficiency. as leucovorin- fluorouracil combination chemotherapy in cancer.

تريتايس ٢٫٥ ملغ Israel - arabă - Ministry of Health

تريتايس ٢٫٥ ملغ

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.